Related Experiment Videos
[Idiosyncratic drug-induced agranulocytosis]
1Service de Médecine Interne, Clinique Médicale B, Hôpitaux Universitaires de Strasbourg, France. emmanuel.andres@chru-strasbourg.fr
La Revue De Medecine Interne
|July 27, 2005
Summary
Drug-induced agranulocytosis, a severe condition causing low neutrophil counts, can be life-threatening. Future management may involve antibiotics and growth factors like G-CSF for critical cases.
Area of Science:
- Hematology
- Pharmacology
- Toxicology
Context:
- Agranulocytosis is a severe adverse drug reaction characterized by extremely low neutrophil counts.
- It is often associated with antibiotics, antithyroid drugs, and ticlopidine, accounting for over 60% of drug-induced cases.
- The incidence ranges from 2.4 to 15.4 cases per million patient-years, with a significant risk of sepsis.
Purpose:
- To review the characteristics, incidence, and clinical presentation of drug-induced agranulocytosis.
- To discuss the current understanding of this severe adverse drug reaction.
- To outline potential future management strategies for drug-induced agranulocytosis.
Summary:
- Idiosyncratic drug-induced agranulocytosis involves neutrophil counts below 0.5x10(9)/l, potentially leading to severe sepsis.
- Despite potential asymptomatic presentation in 50% of cases, neutropenia can cause fever, septicemia, and localized infections.
- With appropriate management, the mortality rate has decreased to approximately 5%.
Impact:
- Highlights the critical nature of drug-induced agranulocytosis and its potential for severe complications.
- Emphasizes the importance of prompt diagnosis and management in reducing mortality.
- Suggests the integration of broad-spectrum antibiotics and hematopoietic growth factors (G-CSF) in future treatment protocols for critically ill patients.